ISTA Pharmaceuticals
 | |
| Subsidiary | |
| Industry | Pharmaceuticals |
| Founded | 1992 |
| Headquarters | Irvine, California |
Key people |
Vicente Anido Jr., Ph.D., President, Chief Executive Officer, Glenn E. Davis, Vice President, Chief Compliance Officer, Marvin J. Garrett, Vice President, Regulatory Affairs, Quality & Compliance, Kathleen McGinley, Vice President, Human Resources & Corporate Services, Kirk McMullin, Vice President, Operations Timothy R. McNamara, PharmD, Vice President, Clinical Research & Medical Affairs Tom Mitro, Vice President, Sales & Marketing |
| Products | Bromday, Bepreve, Xibrom, Istalol, Vitrase |
| Website |
www |
ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specializes in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye.[1] ISTA was acquired by Bausch & Lomb on March 26, 2012.[2]
In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.[3]
Products
- Bromday (bromfenac ophthalmic solution) 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction[4]
- Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of itching associated with signs and symptoms of allergic conjunctivitis[5]
- Xibrom (bromfenac ophthalmic solution) 0.09% for the treatment of inflammation and pain following cataract surgery (no longer being manufactured as of February 2011)
- Istalol (timolol maleate ophthalmic solution) 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma[6]
- Vitrase (hyaluronidase injection) Ovine, 200 USP Units/mL for use as an adjuvant to increase the absorption and ispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents[7]
Litigation
On May 24, 2013, ISTA Pharmaceuticals entered a guilty plea to federal felony charge of conspiracy to introduce a misbranded drug into interstate commerce and conspiracy to pay illegal remuneration in violation of the Federal Anti-Kickback Statute. ISTA agreed to pay $33.5 million to resolve criminal and civil liability arising from its marketing, distribution and sale of its drug Xibrom.[8]
References
- ↑ "ISTA: Profile for ISTA Pharmaceuticals, Inc. - Yahoo! Finance". Finance.yahoo.com. Retrieved 2009-10-28.
- ↑ http://dealbook.nytimes.com/2012/03/26/bausch-lomb-to-buy-ista-pharmaceuticals-for-500-million/
- ↑ http://dealbook.nytimes.com/2012/09/04/valeant-continues-its-string-of-acquisitions/?rref=collection%2Ftimestopic%2FMedicis%20Pharmaceutical%20Corporation&_r=1
- ↑ http://www.istavision.com/products/bromday.html
- ↑ http://www.bepreve.com/
- ↑ http://www.istavision.com/products/istalol.html
- ↑ http://www.istavision.com/products/vitrase.html
- ↑ https://www.justice.gov/opa/pr/ista-pharmaceuticals-inc-pleads-guilty-federal-felony-charges-will-pay-335-million-resolve